“Every day here is stimulating.”

Research and Development

David Blum

Global Head, Neurology Clinical Research

Sunovion Career Milestones

  • NDA approval, eslicarbazepine acetate (APTIOM®) 2013
  • NDA approval, Eslicarbazepine acetate for monotherapy 2015
  • Collaborated in the management of a Phase 2 clinical trial

What are you currently researching?

  • Eslicarbazepine acetate for pediatric epilepsy
  • APL-130277 for Parkinson’s disease
  • Neuropathic pain

What breakthroughs are you hoping to see in your specialty area?

I’m proud of Sunovion’s continued focus on advancing innovative new therapeutic options for neurological disorders, which includes new indications and delivery methods, as well as incorporating digital health approaches.

Describe your career at Sunovion

I have been at Sunovion since 2010. Sunovion is a nice balance between large company expertise and small-company innovation. We have a diverse staff of brilliant, hard-working people, in both the scientific and commercial sides of the organization. Every day here is stimulating. There’s free coffee and plenty of entertainment.